MAPK8/JNK1 inhibitors have been developed for cancer therapy [103–106] and specifically for prostate cancer cells, as MAPK8/JNK1 inhibits autophagy and promotes survival and proliferation of cancer cells in an androgen-independent manner. Here, MAPK8 is linked to prostate cancer.